ERIC AGUIAR, MD RYAN BELTRAMINI

ERIC AGUIAR, MD

Partner, Aisling Capital

Dr. Aguiar joined Aisling in 2016 and serves as a Partner. Prior to Aisling, Dr. Aguiar was a partner at Thomas, McNerney and Partners, a $600 million healthcare-focused venture capital and growth equity fund, from 2007 to 2015. Dr. Aguiar was a Managing Director of HealthCare Ventures, a healthcare venture capital fund, from 2001 to 2007. He was CEO of Genovo, Inc., a biopharmaceutical company that specialized in gene delivery and gene regulation. He was also executive director of TheraTech, Inc. He was a Vice President and Managing Director of Philadelphia Ventures from 1992 to 1997.

Dr. Aguiar currently serves as a director of BridgeBio Pharma, Eidos Therapeutics and Invitae, and as a board observer of PellePharm. His prior board service includes Amarin, CardioKine, Metaphore (merged with ActivBiotics), Oriel Therapeutics (acquired by Novartis),

SkinMedica, Virdante Pharmaceuticals (acquired by Momenta) and 3-D Pharmaceuticals. Dr. Aguiar is a member of the Board of Overseers of the Tufts School of Medicine and a member of the Council on Foreign Relations.

Dr. Aguiar received his M.D. with honors from Harvard Medical School and his B.A. with honors from Cornell University as a College Scholar. He was also a Luce Fellow and is a Chartered Financial Analyst.

RYAN BELTRAMINI

KATHY BERNSTEINSSON

Managing Director, Morgan Stanley

Kathy Bergsteinsson is a Managing Director in equity capital markets at Morgan Stanley and leads the healthcare team. She has managed over 60 healthcare IPOs for the firm and raised over $80 billion in equity for issuers across 200+ transactions including IPOs, follow-ons, convertibles and private placements. Kathy first joined the firm in 2005 in the

mergers and acquisitions department. Prior to joining Morgan Stanley, she held various positions in venture capital, investment banking and not-for-profit. She received her MBA from The Wharton School at the University of Pennsylvania and a BS in Industrial Engineering from Stanford University.

STEPHEN BERNSTEIN

Co-Chair, Life Sciences Industry Group

McDermott Will & Emery

Stephen W. Bernstein specializes in e-health, “big data”, data

engineering, deployment of digital health tools and solutions and health-related matters affected by the internet and the Health Insurance

Portability and Accountability Act (HIPAA), as well as private equity investments, mergers, acquisitions, affiliations and joint ventures

involving technology, digital health companies, hospitals and physicians. Stephen leads the Firm’s Digital Health Practice, which brings together McDermott lawyers from within and outside the Health Industry Advisory Practice Group to develop thought leadership, share information and collaborate on best practices, and is co-chair of the Firm’s Life Sciences Practice. Stephen served as global head of the Firm’s Health Practice from 2009-2018. He is a current member of the Firm’s Management Committee and has served on the Firm’s

JENNIFER BOCK

Attorney, McDermott Will & Emery

Jennifer Bock focuses her practice on representing public, private and emerging companies and investors in domestic and cross-border mergers and acquisitions, finance, joint ventures, private equity investments and other business transactions. Jennifer has advised companies on corporate issues in a wide range of industries, including the consumer goods, technology, health/life sciences, industrial and energy industries.

STEVE BOSSONE

Senior Vice President, Chief Patent Counsel,

Alnylam

Steve Bossone has worked at Alnylam Pharmaceuticals since 2010 and is currently senior vice president/ chief patent counsel at the company. He obtained his PhD in Experimental Pathology from Stony Brook University with post-doctoral training at Harvard Medical School and subsequently his JD in IP from Suffolk University Law School, and since graduating he has had various roles in pharmaceutical companies, including working as senior patent counsel at EMD Serono from 2004 to 2007 and Shire Human Genetics Therapies from 2007 to 2010.

KRISTIE BRADFORD

Director, Intellectual Property, IBM

Corporation

As Director of Intellectual Property at IBM, Kristie is responsible for monetizing select technology investments, from strategy development to transaction execution. Her focus areas include blockchain, artificial intelligence (AI), and monetization via Venture Capital and Private Equity channels.

Most recently, Krstie co-led mergers and acquisitions (M&A) and strategic partnerships for IBM Watson Health (2016-2019).

GABRIELE BRAMBILLA

CEO, Alira Health

Gabriele Brambilla was appointed Alira Health’s Chief Executive Officer in 2014 and has led U.S. operations since 2010. In his role as CEO, Gabriele continues to develop Alira Health’s corporate and product lifecycle capabilities and help our clients to accelerate their innovation.

In 2018 he co-founded the MetroWest Life Sciences Network, a regional collaboration of healthcare and life science-based organizations,

municipalities, and economic and business development organizations located in Boston’s MetroWest region, which is home to Alira Health’s headquarters. His work as the Chairman of this thriving network is helping to bring greater collaboration, innovation, and entrepreneurship to this critical life sciences ecosystem. Gabriele is also on the Board of Directors of EnlightenVue, WoundForce, Firefly, and Computational Life. In 2019, Gabriele was named Business Leader of the Year by the MetroWest Chamber of Commerce.

TOM BRIDA

General Counsel, Chief Compliance Officer,

Invitae

Tom leads the legal and compliance team at Invitae. Tom has a broad-based legal background in the life science and diagnostic industries, having advised both public and private multinational companies on transactional and corporate matters. Prior to joining Invitae, Tom served as associate general counsel at Bio-Rad Laboratories and associate in Orrick's corporate and technology group. Tom holds a B.A. from Stanford University and a law degree from U.C. Berkeley School of Law.

JIAYAN CHEN

Partner, McDermott Will & Emery

Jiayan Chen counsels clients on a range of regulatory, transactional, and strategic issues that arise in the context of efforts to leverage data, bioassets, and technology to drive innovation and quality in health care. Jiayan has particular experience with complex, cutting-edge “Big Data” transactions and initiatives designed to advance precision medicine and the use of real-world data.

Jiayan counsels a broad array of clients, including health care technology companies, data companies, health systems, academic medical centers, professional associations, and life sciences companies.

DIANA CHIU

Vice President, Assistant General Counsel

and Assistant Secretary, Agilent

P. Diana Chiu is vice president, assistant general counsel and assistant secretary of Agilent Technologies. She is responsible for mergers and acquisitions, corporate governance and securities matters.

She joined Agilent in 2013 as senior counsel.

Before that she worked at Pillsbury Winthrop Shaw Pittman, LLP, a law firm in Palo Alto, California. There she represented public and private technology companies on a broad range of corporate and securities matters. She was also seconded to Sumitomo Chemical Co. Ltd.’s legal department in Tokyo, where she managed an array of in-house legal issues. Prior to that she was corporate counsel at Marvell Technology, Inc.

Chiu is a graduate of the University of Virginia School of Law. She also received a master’s degree in health administration from the University of Southern California and a bachelor’s degree in biochemistry from the University of California, Berkeley. She is an active member of the State Bar of California.

SARAH COLUMBIA

Partner, McDermott Will & Emery

Sarah Chapin Columbia is a Fellow in the American College of Trial Lawyers. Over the last nine years, she has led 14 patent infringement and invalidity trials (eight jury trials, six bench trials) across several jurisdictions, including the federal courts in Massachusetts, Florida, Delaware, California and Texas.

Sarah counsels clients on overall intellectual property strategy and positioning, including litigation avoidance. She also provides strategic guidance in complex transactions in which intellectual property assets often are critical to a successful deal.

DENNIS CROWLEY

Senior Vice President, Business

Development & Licensing, Baxter

Dennis Crowley is senior vice president, Business Development & Licensing.

Crowley joined Baxter in 2017 from Acelity L.P., where he served as senior vice president, Strategy and Business Development. Previously, he worked at Medtronic plc (and before that, Covidien plc) in roles of increasing responsibility between 2005 and 2015, most recently as vice president, Corporate Development. Crowley began his professional career with Tyco Healthcare in 1993 and served in various strategic, business development and operational roles during his 12-year tenure. Crowley received his bachelor’s degree in economics from Harvard College.

ANDREW ElBARDISSI, M.D.

Partner, Deerfield Management

Andrew ElBardissi, M.D., is a Partner on the Medical Devices team at Deerfield and joined the Firm in 2017. Prior to Deerfield, Dr. ElBardissi was a Principal at Longitude Capital, where he focused on investments in medtech and biotechnology. Before that, he was an Associate in JPMorgan’s healthcare investment banking practice. Dr. ElBardissi received residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. He has been independently funded by the

National Institutes of Health and the Agency for Healthcare Research and Quality, has authored over 30 publications in leading peer-reviewed scientific journals and has presented his research at numerous medical and surgical conferences. Dr. ElBardissi holds an M.D. from the Mayo Clinic, an M.P.H. in Quantitative Methods from Harvard University, an M.B.A. from Harvard Business School and a B.S. with honors in Biology (Phi Beta Kappa) from the Schreyer Honors College at the Pennsylvania State University

.

TODD FINGER

Partner, McDermott Will & Emery

Todd Finger represents clients in the full range of corporate transactions and financings, including mergers, stock and asset purchases and sales, leveraged buyout transactions, venture capital investments, joint ventures, restructurings and recapitalizations. Todd advises clients with interests and operations in the life sciences, consumer products, food and beverages, entertainment and media, and fashion and apparel industries, among other sectors. Todd is head of the New York office’s

Transactions Practice Group and co-managing partner of the New York office. Todd is also a member of the Firm-wide Management

BRIAN FORTUNE

Senior Managing Diretor, Farragut Square

Group

As Farragut’s President and Political Strategist, Brian leads FSG’s Washington team and is responsible for the firm’s research and diligence work. Before co-founding Farragut, Brian was the Political Strategist and a Managing Director of Marwood. Previously, he served the

Republican leadership in the U.S. House of Representatives for a decade, working primarily for former Speaker John Boehner (R-OH) and

Majority Leader Dick Armey (R-TX).

While representing the House leadership, Brian served as Staff Director of Legislative Digest, the policy analysis and communications division of the House Republican Conference. In that role, he worked with the senior staff on all House committees, concentrating primarily on issues before the Ways and Means, Energy and Commerce, and Appropriations Committees. During this period, Brian worked directly with leadership on all of the major healthcare initiatives, including BBA97, BBRA, HIPAA and BIPA 2000. He is a graduate of Oregon State University.

ANNA FRENCH

Principal, Qiming Venture Partners

Anna French, PhD joined Qiming Venture Partners USA in 2017 and is based in Cambridge, MA. Prior to joining the Qiming team, Anna was a management consultant at the Boston Consulting Group (BCG) where she advised leading biopharma companies on their strategy and

operations. She also led a global industry-academic consortium focused on cell therapy.

JENNIFER GEETTER

Partner, McDermott Will & Emery

With a practice focused primarily on the development, delivery and implementation of digital health solutions, data and research, Jennifer S. Geetter works closely with both adopters and developers to bring their innovative healthcare solutions to patients and providers. In order to design and deploy digital health technologies effectively, Jenn offers valuable guidance on key issues, like patient on-boarding, provider implementation, privacy and regulatory issues. She advises global life sciences, healthcare and informatics clients on legal issues attendant to digital health, biomedical innovation, research compliance, global privacy and data security laws, and financial relationship management.

DAVID HAIGH

Managing Director and Co-Founder, Atlantic

Global Risk

David is a Managing Director and Co-Founder of Atlantic. David is responsible for management of deal execution and implementing Atlantic’s growth initiatives. David and his team work with leading financial sponsors and strategic clients across a variety of sectors, supporting transactions between $5m and $18bn in enterprise value. David is a thought leader in the M&A insurance space and speaks regularly at industry events about market trends and best practices. Prior to joining Atlantic, David was head of North American transactions for a leading European M&A insurance broker. In his previous role, David supported financial sponsors and corporates on inbound, outbound and intra-North American transactions. David started his career in the Energy Sector, working as a project engineer for Oil & Gas and Defense projects.

MARSHALL JACKSON, JR

Partner, McDermott Will & Emery

Marshall E. Jackson, Jr. focuses his practice on transactional and regulatory counseling for clients in the healthcare industry, as well as advises clients on the legal, regulatory and compliance aspects of digital health. Marshall advises healthcare providers, private equity firms and their portfolio companies, and technology companies involved in “digital health” – the intersection of health software applications, analytical tools, medical technology and electronic data assets enabled by the Internet and mobile devices –on a variety of legal, regulatory and compliance matters with a particular focus on digital health topics, including telehealth, telemedicine, mobile health and consumer wellness. Such engagements include assisting clients in developing and

implementing telehealth programs by advising on issues related to professional licensure, scope of practice, informed consent, prescribing and reimbursement.

LAURA JEHL

Global Head of Privacy and Cybersecurity

Practice, McDermott Will & Emery

Laura Jehl serves as global head of the Firm’s Privacy and Cybersecurity Practice. Focusing on the intersection of data, law and emerging

technologies, Laura advises clients on a broad range of privacy and cybersecurity issues. She has extensive experience identifying and mitigating privacy and data protection issues arising out of the

collection, use and storage of data as well as the design of new business models, products and technologies. With unique experience as a former senior in-house counsel and C-suite executive, she understands the business, legal and technological challenges and opportunities her clients face and helps develop innovative approaches to maximize the value of their data-based assets

.

BYRON KALOGEROU

Partner, McDermott Will & Emery

Byron S. Kalogerou is the founder of the Firm’s Life Science Industry Group and is the senior partner in the Boston Corporate Practice. He focuses his practice on domestic and cross-border mergers and

acquisitions, finance, and joint ventures and alliances. He has substantial on-the-ground experience structuring mergers, acquisitions, divestitures and joint ventures on six continents. Byron has extensive industry background in the life science, industrial and manufacturing sectors. He also acts as outside general counsel to a number of companies.

DEBBIE LIN

Executive Director, Boehringer Ingelheim

Venture Fund

Dr. Debbie Lin is Executive Director at Boehringer Ingelheim Venture Fund in the US and leads the Fund’s North American efforts in Digital Healthcare. She joined Boehringer Ingelheim Pharmaceuticals in 2008. Within Boehringer Ingelheim Pharma, she worked across various regions and divisions. She has worked in Medical Affairs in the area of women’s health and later in Health Economics and Outcomes supporting all commercial product sales with large payers and providers accounts on the West Coast. She also led the US organization’s social

entrepreneurship program in Boehringer Ingelheim’s Making More Health collaboration with Ashoka.

In 2013, she transitioned to Corporate Headquarters in Germany in Corporate Strategy and Development as Director of Corporate

Development. There she was responsible for BI’s global development strategy, leading BI’s global venture into stroke rehabilitation. She led multi-country teams to set up the company’s first stroke rehabilitation centers in Shanghai, China and in Lisbon, Portugal. Prior to Boehringer Ingelheim, she worked as a Public Policy Consultant for Pacific Health Policy Group supporting Medicaid Policy implementation in various states such as Vermont and West Virginia during the Clinton

Administration. Her doctorate is in Pharmacogenomics and

Bioinformatics from UCSF, she also has a Masters in Engineering from Stanford University and a Masters in Public Policy from UCLA.

JOANNA LIN

Partner, McDermott Will & Emery

Joanna Jung-Erh Lin focuses her practice on corporate, securities and transactional matters. Along with many types of transactions, she handles domestic and cross-border venture financing, mergers and acquisitions for public and private companies, and complex transition services agreements. She also has experience with capital markets transactions, having represented US and international issuers, investment banks and investors in a wide range of securities offerings, including initial public offerings (IPOs), follow-on offerings and private

placements of equity securities. Joanna also regularly counsels clients on matters ranging from corporate governance to US Securities and

Exchange Commission periodic reporting requirements and other general corporate matters

.

BRIAN MALKIN

Partner, McDermott Will & Emery

Brian Malkin counsels pharmaceutical and biologic clients on Food and Drug Administration (FDA) regulatory matters and intellectual property (IP) law, with an emphasis on patent litigation. His practice at the intersection of FDA- regulated products and patent law makes him a valuable partner to drug manufacturers, biotechnology clients, medical device companies and cannabis companies as they develop new products and protect their innovations though life cycle management, bring their products to market and pursue transactional opportunities

.

PATRICE MCNICOLL

Co-Head of Investment Banking, B. Riley

Securities, Inc.

Patrice McNicoll is currently the Co-Head of Investment Banking at B. Riley Securities, Inc. Prior to joining B. Riley, Mr. McNicoll created and served as Chief Executive Officer of MLV & Co., a boutique investment bank which he sold to FBR in 2015. Mr. McNicoll was a managing director at Cantor Fitzgerald & Co, in New York where he played a key role in originating revenues and building the firm's investment banking practice. Mr. McNicoll structured and executed various capital market transactions for small and large Real Estate Investment Trusts and companies in the energy, technology, biotechnology, and shipping sectors. Mr. McNicoll received a Bachelor of Arts with Honors in Economics from York University, in Toronto, Canada and a Master of Business Administration with a concentration in finance from McGill University, Montreal, Canada.

MARIAN NAKADA

Vice President, Venture Investments,

Johnson & Johnson Innovation

Marian Nakada, VP Venture Investments for Johnson & Johnson Innovation – JJDC, has almost 30 years of experience in the

pharmaceutical industry, starting her career at the laboratory bench at Centocor and moving to a research leadership role before Centocor’s acquisition by Johnson & Johnson in 1999. She transitioned to Janssen Business Development where she executed deals to support the

expansion of the Biologics portfolio. She joined JJDC, Johnson & Johnson’s corporate venture group in 2013. She is passionate about leveraging Johnson & Johnson’s capabilities to help her portfolio companies succeed. Marian has a B.A. in Biology from Harvard College and a Ph.D. in Pharmacology from the University of Pennsylvania. She is currently on the Boards of Navitor

Pharmaceuticals, Twenty-eight Seven Therapeutics, Ribon Therapeutics as well as the New England Venture Capital Association where she is working to champion change as an active contributor to its Diversity & Inclusion Committee.

NATHAN PELZER

Founder and CEO, Clinify Health

Nathan Pelzer is the Founder and CEO of Clinify Health, a digital health company that works with physician practices located in underserved communities to achieve financial stability and remain independent. Prior to founding Clinify, Nathan was the Head of Corporate Strategy for VillageMD a national primary care provider organization located in Chicago where he was responsible for coordinating strategic initiatives to improve patient health outcomes while reducing overall cost of care. Prior to this role Nathan spent his career in senior level positions within the advisory services firms working across various aspects of the healthcare industry. Nathan has a B.S. in Finance from The University of Minnesota and an M.B.A. from the University of Chicago – Booth School of Business.

ROB PEREZ

Operating Partner, General Atlantic;

Founder, Life Science Cares

Rob Perez is an Operating Partner and part of General Atlantic’s Operations Group, providing strategic support and advice to the firm’s investment team and portfolio companies in the Life Sciences sector. Before joining General Atlantic in 2019, he was Managing Director of Vineyard Sound Advisors, LLC, an advisory practice focused on growth companies in the biopharma industry. Prior to that, Rob was President and CEO of Cubist Pharmaceuticals, Inc. before its sale to Merck in 2015. Before joining Cubist in 2003, he served as Vice President of Biogen, Inc.’s CNS Business Unit.

VERNESSA POLLARD

Chair, FDA Practice, McDermott Will &

Emery

Vernessa Pollard works alongside life sciences, medical device and technology companies, helping them navigate US Food and Drug Administation (FDA) regulatory complexities to bring novel

technologies and cutting-edge products to market. As a trusted advisor and legal strategist for multi-national life science companies, start-ups and investors, she helps clients develop practical, scalable and

innovative strategies for solving challenging regulatory and compliance problems, evaluating risk and achieving business objectives.

RENE QUASHIE

Vice President, Policy and Regulatory Affairs,

Digital Health, Consumer Technology

Association

René Quashie is the first-ever Vice President of Policy & Regulatory Affairs of Digital Health at the Consumer Technology Association. Quashie provides guidance on key technical and regulatory issues relating to consumer digital health and wellness technology products, services, software and apps. Quashie will also work on behalf of CTA’s Health and Fitness Technology Division , which supports the consumer health technology industry through education, research, standards work, policy initiatives and more. The division’s industry-consensus

accomplishments include the creation of CTA’s Guiding Principles on the Privacy and Security of Personal Wellness Data , addressing how companies should treat consumers’ personal wellness data. CTA works closely with the Food and Drug Administration, the Centers for

Medicare and Medicaid Services, the Office of the National Coordinator and other related government agencies. Quashie previously was in private law practice at several national firms, and earned his law degree from George Washington University.

VIVEK RAMASWAMY

Founder and CEO, Roivant Sciences

Vivek Ramaswamy is Founder and Chief Executive Officer of Roivant Sciences. Roivant advances the development and delivery of important medicines in disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal needs. Roivant also builds technology-focused subsidiaries focused on improving the process of developing and commercializing medicines. Roivant and its family of companies employ over 900 professionals today.

Mr. Ramaswamy graduated summa cum laude in Biology from Harvard University in 2007 and began his career as a successful biotech investor where he oversaw investment in numerous companies, including those that helped develop curative treatment regimens for hepatitis C virus. He continued to work as an investor while earning his law degree from Yale Law School, where he was a Paul & Daisy Soros Fellow.

MICHAEL RYAN

Partner, McDermott, Will & Emery

With deep experience in the life sciences industry, Michael W. Ryan advises manufacturers, healthcare providers, drug and technology developers, and investors on the legal, regulatory and reimbursement issues that arise during the development and commercialization of medical devices, clinical laboratory testing services, biological products and drugs. He guides life sciences companies and laboratories by

evaluating and implementing strategies to optimize coding, coverage and payment for novel technologies. Michael also helps innovative

companies identify and navigate applicable FDA regulatory

requirements for new technologies, particularly in vitro diagnostics and digital health products. In particular, he regularly advises clients on the FDA’s evolving requirements for laboratory developed tests (LDTs) and digital health products, such as clinical decision support (CDS) software.

FREDERIC SCAEROU

Lead Director, Business Development &

Licensing, Oncology, Servier

Pharmaceuticals

MICHAEL SIEKMAN

Partner, McDermott Will & Emery

Michael Siekman focuses his practice on intellectual property matters, including patent prosecution, licensing and post-grant proceedings and litigation. Leveraging over 25 years of experience, Michael has built in-depth patent portfolios, advising clients in the biotechnology and pharmaceutical industries.

Michael keeps clients’ business goals in mind as he regularly provides legal counsel in the litigation matters, including Hatch-Waxman matters, and post-grant solutions for biosimilars. He has successfully led matters before the Patent Trial and Appeal Board (PTAB) and the European Patent Office. His licensing practice involves IP-related aspects of mergers, acquisitions, IPOs and other financing and licensing programs.

RICHARD SMITH

Counsel, McDermott Will & Emery

Richard B. Smith focuses his practice on representation of life sciences companies and related transactions. He has served as counsel to public, private and emerging life sciences companies, advising those companies on strategic business transactions such as licensing, joint ventures, and collaborations involving research, development, marketing, supply, clinical development and co-promotion of pharmaceutical, diagnostic and medical device products.

Richard also advises companies on other corporate issues common to life sciences companies, including corporate formation of new ventures, venture capital, private equity, and venture philanthropy.

EMMANUELLE TROMBE

Partner, McDermott Will & Emery

Emmanuelle Trombe represents pharmaceutical, medical device and bio-pharmaceutical companies globally in transactional matters in relation to M&A and divestitures, joint ventures and strategic partnerings, large-scale projects, outsourcing projects, product development, licensing agreements and regulatory matters. She also advises venture capital funds and bio-pharmaceutical companies in connection with a broad range of financing activities.

Emmanuelle Trombe is distinguished in Chambers Europe and Legal 500 EMEA in life sciences transactions, where she is recommended for her expertise in the pharmaceutical, health care, biotech and medical devices industries and described as very responsive, smart, flexible and business-minded.

KWAME ULMER

Venture Partner, Wavemaker Three-Sixty

Health; Founder, MedTech Color

Kwame Ulmer is a venture partner at Wavemaker Three-Sixty Health - the leading Southern-California based, early stage venture capital firm (Seed and Series A) focused on the healthcare industry. He participates in all aspects of fund management (e.g. deal sourcing, diligence, negotiation and advising portfolio company management teams). Kwame brings nearly twenty years of experience evaluating medical technologies in the government and private sector, and serving in senior operating roles at medical device companies. He has personally

evaluated more than 1,000 medical technologies in his career. Kwame spent 12 years at the U.S. Food and Drug Administration (FDA) in progressive leadership roles, including Deputy Director and Branch Chief. He also served as Vice President, Regulatory Affairs and Quality Assurance at Implant Direct, a Danaher Corporation operating company. He is a member of the Executive Committee of Tech Coast Angels (LA), the world’s largest angel investing network and serves on the steering committee of ScaleLA, the leading healthcare innovation space in Los Angeles. Kwame earned his B.S. in Physics from Lincoln University, and has two Masters degrees from the University of Virginia, in Materials Engineering and Business Administration.

SUSAN VAN METER

Executive Director, AdvaMedDx

Susan Van Meter is executive director of AdvaMedDx. AdvaMedDx represents manufacturers of in vitro diagnostic (IVD) tests and technologies. AdvaMedDx member company innovations allow early detection of disease, facilitate evidence-based medicine, improve patient health and health care, and enable personalized medicine, while often lowering overall health care costs. AdvaMedDx is the only advocacy organization exclusively addressing policy issues facing diagnostics manufacturers in the U.S. and around the world.

AdvaMedDx operates as a division of AdvaMed, the Advanced Medical Technology Association. AdvaMed is the world’s largest medical technology association, with over 400 member companies that develop medical devices, diagnostic tools, and health information systems. Ms. Van Meter holds undergraduate and graduate degrees from Villanova University and Boston University, respectively.

KRISTIAN WERLING

Co-Chair, Life Sciences & Program Co-Chair,

McDermott Will & Emery

Kristian (Krist) Werling is co-chair of the Firm’s Life Sciences Practice. He represents biopharmaceutical manufacturers and health care service providers in a wide variety of transactional matters. He also represents private equity and venture capital investors in investments in the life sciences and health care industries. In this capacity, he works with cross-disciplinary teams to conduct legal due diligence and execute platform and add-on acquisitions and divestitures, as well as provide ongoing legal services to portfolio companies. In the health care services arena, Krist has particular experience with transactions and joint ventures involving ambulatory surgical centers, specialty hospitals, dermatology, pain management and anesthesia physician practices and dental practice management companies.

Krist had several years of experience serving as in-house counsel to Hospira, Inc., a generic specialty pharmaceutical and medical device manufacturer that was sold to Pfizer.

RODNEY WHITLOCK, Ph.D.

Vice President, McDermott+Consulting

Rodney is an accomplished health care executive with more than two decades on the Hill where he specialized in rural health, the health care safety net and disability policy.

With nearly 25 years of experience, Rodney possesses and offers clients the kind of knowledge that is uniquely available to those who have drafted and advanced legislation. He strategically guides clients through dense Medicare and Medicaid issues that have significant business impact.

CHUCK WILSON

President and CEO, Cogent Biosciences

Chuck serves as President and CEO of Cogent Biosciences. Before founding Cogent, Chuck led partnering for Novartis research, and was responsible for all efforts in drug discovery up through Phase II clinical development. He brings deal experience in biotech and academic collaborations, product in-licensing, spin-outs, and strategic equity investing in early stage companies. Prior to Novartis, Chuck held both scientific and business management roles in biotechnology. Chuck received his PhD from the University of California, San Francisco, and completed his post-doctoral training at Harvard University /

Massachusetts General Hospital. In addition to his responsibilities at Cogent, Chuck serves as a director on the board of Gigagen, Inc. and as vice chair of the Massachusetts Biotechnology Council (‘MassBIO’).

ALAN WRIGHT

Chief Scientific Officer, Roche Diagnostics

As the Chief Scientific Officer for Roche Diagnostics Corporation, Dr. Wright serves as its lead clinical and policy spokesperson on all aspects of clinical diagnostic medicine. Dr. Wright directs all of Roche

Diagnostics Corporation’s medical and scientific engagements for inline and pipeline products, including those related to infectious diseases and antimicrobial stewardship.

As a physician with extensive background in the managed care,

pharmaceutical and biotechnology industries, and with deep knowledge about regulatory, payer policy and legislative issues affecting healthcare, he is uniquely positioned to help advance medical ideas and technologies from conception to clinical practice.

He earned his medical degree from University of Pennsylvania School of Medicine and a Masters of Public Health degree from Johns Hopkins School of Public Health and Hygiene. He resides in Indianapolis, Indiana, and maintains a farm with his wife and several million bees in Maryland

ERIC ZIMMERMAN

Global Head of Health Practice, McDermott

Will & Emery

Eric Zimmerman is a recognized Medicare law and policy authority and registered lobbyist who represents clients before Congress and

administrative agencies, and helps clients navigate federal legislative and regulatory processes related to Medicare coverage, coding,

reimbursement and compliance. He primarily counsels and represents hospitals and health systems, ambulatory surgery centers, clinical laboratories, pharmaceutical, biotechnology and device manufacturers and suppliers, medical trade associations and professional societies. Eric is the global head of McDermott’s Health Practice. He also serves as a principal of McDermott+Consulting LLC, McDermott’s integrated health-focused policy, lobbying and data analytics consultancy.